Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

December 31, 1999

Study Completion Date

May 31, 2001

Conditions
Lung Cancer
Interventions
DRUG

gemcitabine hydrochloride

DRUG

tacedinaline

Trial Locations (16)

27609

Raleigh Hematology/Oncology Associates - Wake Practice, Raleigh

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

38117

West Clinic, P.C., Memphis

43210

Arthur G. James Cancer Hospital - Ohio State University, Columbus

48201

Barbara Ann Karmanos Cancer Institute, Detroit

78705

Southwest Regional Cancer Center, Austin

90048

Cedars-Sinai Comprehensive Cancer Center, Los Angeles

02111

New England Medical Center Hospital, Boston

48109-0752

University of Michigan Comprehensive Cancer Center, Ann Arbor

T6G 1Z2

Cross Cancer Institute, Edmonton

V3V 1Z2

British Columbia Cancer Agency - Fraser Valley Cancer Centre, Surrey

V5Z 4E6

BC Cancer Agency, Vancouver

V8R 1J8

British Columbia Cancer Agency - Vancouver Island Cancer Centre, Victoria

K1H 8L6

Ottawa Regional Cancer Center - General Division, Ottawa

M5G 1X5

Mount Sinai Hospital - Toronto, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY